QDENGA Dengue Vaccine to Launch in India by 2027
India is set to receive a new dengue vaccine, QDENGA, which will be marketed by Dr. Reddy's Laboratories starting in 2027.
Source: GNews India BiotechThe QDENGA dengue vaccine, developed by Takeda Pharmaceutical Company Limited, is expected to be available in the Indian market by 2027. Dr. Reddy's Laboratories will be responsible for selling and distributing the vaccine across India. This partnership aims to address the significant public health challenge posed by dengue fever in the country. QDENGA is a live-attenuated tetravalent vaccine, meaning it targets all four serotypes of the dengue virus. It has already received regulatory approvals in several countries, including the European Union, the UK, Brazil, and Indonesia. The introduction of QDENGA is a crucial step in India's fight against dengue, a mosquito-borne viral disease that causes widespread illness and mortality annually. Dr. Reddy's will leverage its extensive distribution network to ensure the vaccine reaches a broad population.
This news is important for competitive exams under Science & Technology (UPSC GS Paper III, SSC General Science). Aspirants should know about new vaccine developments, public health initiatives, and major pharmaceutical collaborations. It highlights India's efforts in disease prevention and the role of private sector in healthcare. Understanding the type of vaccine (live-attenuated tetravalent) and its target disease (dengue) is also crucial for exam questions related to biology and health.
- QDENGA dengue vaccine is expected to launch in India by 2027.
- Dr. Reddy's Laboratories will market and distribute the QDENGA vaccine in India.
- The vaccine, QDENGA, is developed by Takeda Pharmaceutical Company Limited.
- QDENGA is a live-attenuated tetravalent vaccine, targeting four dengue virus serotypes.
- Dengue is a mosquito-borne viral disease prevalent in tropical and subtropical regions.
- QDENGA has received regulatory approvals in countries like the EU, UK, and Brazil.
QDENGA is a live-attenuated tetravalent vaccine developed by Takeda Pharmaceutical Company. It is designed to protect against all four serotypes of the dengue virus. The vaccine is administered in two doses and has shown efficacy in preventing dengue fever in clinical trials. It represents a significant advancement in global efforts to control dengue.
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company headquartered in Hyderabad. Founded in 1984, it manufactures and markets a wide range of pharmaceutical products globally. The company focuses on active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter products. It plays a key role in healthcare access in India.
Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms include high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash. In severe cases, it can lead to dengue hemorrhagic fever, a life-threatening condition. It is transmitted primarily by Aedes aegypti mosquitoes.
Exams often ask about new vaccines, their types (e.g., live-attenuated, mRNA), the diseases they target, and the companies involved. Be prepared for questions on mosquito-borne diseases and public health initiatives in India.
Remember 'QDENGA' for 'DENGue' protection, brought to India by 'Dr. Reddy's' in '2027'.
Frequently Asked Questions
When will the QDENGA dengue vaccine be available in India?
The QDENGA dengue vaccine is projected to be available in the Indian market starting in 2027. Dr. Reddy's Laboratories will handle its distribution and sales across the country.
Which company developed the QDENGA vaccine?
The QDENGA vaccine was developed by Takeda Pharmaceutical Company Limited, a Japanese multinational pharmaceutical firm. They have partnered with Dr. Reddy's for its launch in India.
What type of vaccine is QDENGA and what does it target?
QDENGA is a live-attenuated tetravalent vaccine. This means it uses weakened forms of the virus to stimulate immunity and is designed to protect against all four serotypes of the dengue virus.